Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination

CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evolution. He walks us through the science and some potential use cases.